HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials Breast Cancer

Purpose ASCO and the College of American Pathologists (ASCO-CAP) recently recommended further changes to the evaluation of human epidermal growth factor receptor 2 gene (HER2) amplification by fluorescent in situ hybridization (FISH). We retrospectively assessed the impact of these new guidelines by using annotated Breast Cancer International Research Group (BCIRG) -005, BCIRG-006, and BCIRG-007 clinical trials data for which we have detailed outcomes. Patients and Methods The HER2 FISH status of BCIRG-005/006/007 patients with breast cancers was re-evaluated according to current ASCO-CAP guidelines, which designates five different groups according to HER2 FISH ratio and average HER2 gene copy number per tumor cell: group 1 (in situ hybridization [ISH]–positive): HER2-to-chromosome 17 centromere ratio ≥ 2.0, average HER2 copies ≥ 4.0; group 2 (ISH-positive): ratio ≥ 2.0, copies
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Diagnosis & Staging, Combined Modality, Clinical Trials, Prognostic Studies, ASCO Guidelines, Breast Cancer, Cancer Biomarkers, Growth Factors & Receptor, Oncogenes Source Type: research

Related Links:

This study aimed to validate whether the recently-proposed prognostic grading system, initial brain metastasis velocity (iBMV), is applicable to breast cancer patients receiving stereotactic radiosurgery (SRS). We focused particularly on whether this grading system is useful for patients with all molecular types, i.e., positive versus negative for EsR, PgR and HER2.Methods and materialsThis was an institutional review board-approved, retrospective cohort study using our database, prospectively accumulated at three gamma knife institutes, during the 20-year-period since 1998. We excluded patients for whom the day of primary...
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
In patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer, HER2 targeted therapies have significantly improved survival.1,2 However, the cardiotoxicity associated with these therapies limits its use in some patients.3 In the metastatic setting HER2 targeted therapies are used until disease progression or toxicity.4,5 Although prolonged trastuzumab therapy may be associated with a higher risk of cardiotoxicity, this is felt to be counterbalanced by survival benefits of HER2 targeted therapy.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Publication date: Available online 25 January 2020Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Mirza Muhammad Faran Ashraf Baig, Wing-Fu Lai, Reyaj Mikrani, Mehreen Jabeen, Muhammad Naveed, Muhammad Abbas, Muhammad Asim Farooq, Anam Ahsan, Said Abasse Kassim, Ghulam Jilany Khan, Muhammad Tayyab AnsariAbstractDNA based nano-carriers synthesized from short circular scaffolds (circular DNA nanotechnology) attains stiffer topology for ligand functionalization (neuregulin-1/NRG-1 ligand) and biological applications (targeted drug delivery). Daunorubicin (DR) is a hydrophobic chemical that requires robust ...
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research
Authors: Kang YJ, Lee HB, Kim YG, Han J, Kim Y, Yoo TK, Lee ES, Moon HG, Noh DY, Han W Abstract Objective: While the value of Ki-67 has been recognized in breast cancer, controversy also exists. The goal of this study is to show the prognostic value of Ki-67 according to progesterone receptor (PgR) expression in patients who have estrogen receptor- (ER-) positive, human epidermal growth factor receptor 2- (HER2-) negative early breast cancer. Methods: The records of nonmetastatic invasive breast cancer patients who underwent surgery at a single institution between 2009 and 2012 were reviewed. Primary end point ...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
CONCLUSION: Patients with amplification of CEP17 had a co-amplified HER2 and were more commonly HER2+, LN positive and grade 3 in the nuclear component of grade. PMID: 31977265 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
Publication date: April 2020Source: Biomedicine &Pharmacotherapy, Volume 124Author(s): Jie Yi, Liwen Ren, Dandan Li, Jie Wu, Wan Li, Guanhua Du, Jinhua WangAbstractBreast cancer (BC) is the most common cancer in women and the second leading cause of their cancer death. Establishing an accurate BC prognosis is very difficult because of its heterogeneity. Elevated TFF1 levels in serum were associated with development of BC, TFF1 expression was upregulated in BC compared to the healthy breast tissue. The aim of this study was to investigate the function of TFF1 in BCs, and to assess whether serum TFF1 could be used in for...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 23 January 2020Source: Cancer CellAuthor(s): Dhivya R. Sudhan, Angel Guerrero-Zotano, Helen Won, Paula González Ericsson, Alberto Servetto, Mariela Huerta-Rosario, Dan Ye, Kyung-min Lee, Luigi Formisano, Yan Guo, Qi Liu, Lisa N. Kinch, Monica Red Brewer, Teresa Dugger, James Koch, Michael J. Wick, Richard E. Cutler, Alshad S. Lalani, Richard Bryce, Alan AuerbachSummaryWe developed neratinib-resistant HER2-mutant cancer cells by gradual dose escalation. RNA sequencing identified TORC1 signaling as an actionable mechanism of drug resistance. Primary and acquired neratinib resistance ...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
Current imaging methods that are used to spot tumors don’t provide much information about the rate of activity of the cells making up the diseased tissues. Breast cancer tumors, for example, are mostly classified into a few categories based on ...
Source: Medgadget - Category: Medical Devices Authors: Tags: Diagnostics Materials Medicine Oncology Radiology Source Type: blogs
Conditions:   Breast Cancer;   Breast Cancer Metastatic Intervention:   Drug: Niraparib 100 MG Sponsors:   MedSIR;   GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The objective was to compare post-operative complication rates among patients treated with partial mastectomy (PM), unilateral mastectomy (UM), and bilateral mastectomy (BM) after NAC.Study design398 patients with breast cancer who had NAC from 2008 to 2016 were identified from a prospectively maintained database. The primary outcome measure was 30-day post-operative morbidity.Results125 patients (31.4%) underwent PM, 107 patients (26.9%) UM, and 166 (41.7%) BM. There was no significant difference among the 3 groups with respect to histology (ductal: 96.0% PM, 88.8% UM, 92.6% BM, p = 0.161). Groups were similar with re...
Source: The American Journal of Surgery - Category: Surgery Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Genetics | HER2 | Herceptin | Pathology | Study